

PRESS RELEASE

Paris, July 28, 2021

Q1 revenue 2021/2022: +12%

Continued commercial momentum

Sustained pace of new SaaS contract signature

Generix Group, Industrial, Logistics and Retail Ecosystems provider with leading Collaborative SaaS Solutions, issued today its revenues for the first quarter of its 2021/2022 fiscal year.

Q1 revenue 2021/2022: +12%

	•	Quarter ended June 30	
Unaudited (K€)	2021	2020	
SaaS	8 186	7 916	3%
Maintenance	4 646	4 467	4%
Licenses	1 177	522	125%
Software revenues	14 009	12 905	9%
Consulting Services	7 234	6 008	20%
Revenues	21 243	18 913	12%

Over the past quarter, Group revenues amounted to €21.2 million, up 12% compared to Q1 2020-2021 and up 6% compared to the pre-health crisis level (€20.1 million in Q1 2019-2020).

Achieved in a still uncertain sanitary context, this performance is mainly driven by:

- The dynamic performance of North America (+78%), Benelux (+31%) and Portugal (+26%);
- Strong license sales on the installed base in France, and also a significant new signature in North America with a customer specialized in the production and distribution of vegetable meat;
- Confirmation of the return to a normative level of Consulting & Services activity (+13% vs Q1 2019-2020).



This sales momentum, in line with what was seen in previous quarters, illustrates the strength of the Generix Group model and the relevance of its solutions to the expectations of supply chain and digitalization markets.

Q1 new SaaS signatures: 1,7 M€

	Quarter ended June 30		Var. Q1 2021 vs Q1
Unaudited (K€)	2021	2020	2020
New SaaS contract signing (ACV*)	1 664	533	212%

^{*}New contracts signed expressed in ACV (Annual Contract Value), emphasize the average annual complementary revenue to be generated after implementing the contracts in question.

In addition to the good momentum of license sales, the growth in new SaaS signatures, already seen in previous quarters, accelerated this first quarter with +212% vs Q1 2020-2021 and +144% vs Q1 2019-2020 (period before health crisis).

These new SaaS contracts, through the Generix Supply Chain Hub platform, were signed mainly in Spain, Brazil and France.

Confirmation of objectives for fiscal year 2021/2022

Generix Group confirms its objectives of continuing to sign new contracts and maintaining investments in R&D and Sales & Marketing, particularly in North America, and anticipates double-digit growth and a stable EBITDA margin for fiscal 2021-2022.

Supplemental and non-IFRS Financial Information

Supplemental non-IFRS information (above-mentioned as EBITDA) presented in this press release is subject to inherent limitations. It is not based on any comprehensive set of accounting rules or principles and should not be considered as a substitute for IFRS measurements. Also, the Company's supplemental non-IFRS financial information may not be comparable to similarly titled non-IFRS measures used by other companies.



Next financial press release: October 27, 2021 after the market closes Publication of revenue for the second quarter of 2021/2022 fiscal year

About Generix Group

Generix Group is a Collaborative Supply Chain expert present in 60 countries, thanks to its subsidiaries and network of partners. More than 6,000 companies around the world use its SaaS solutions. The group's 750 employees provide daily support for such customers as Carrefour, Danone, FM Logistic, Fnac-Darty, Essilor, Ferrero and Geodis in the digital transformation of their Supply Chain.

Its collaborative platform, **Generix Supply Chain Hub**, helps companies to keep the promises they make to their customers. It combines the capabilities to execute physical flows, digitalize information flows, manage collaborative processes and connect companies to all their partners, in real time.

Generix Supply Chain Hub is aimed at all players in the Supply Chain: manufacturers, third- and fourth-party logistics providers (3PL/4PL) and retailers.

www.generixgroup.com

Founded in France in 1990, the company is listed on the Eurolist market of Euronext Paris, compartment C (ISIN: FR0010501692). To learn more: www.generixgroup.com